Riesgo de trombosis asociado a agentes estimulantes de la eritropoyesis. Revisión sistemática

Abstract

Introduction: The relationship between erythropoietic colony-stimulating factors and pre-existing pathologies predisposes to thrombotic disease through various mechanisms, which are not yet fully established. Additionally, erythropoiesis-stimulating agents may increase platelet count due to megakaryocyte activation, which influences thrombus formation.

Objective: To determine the risk of thrombosis associated with erythropoiesis-stimulating agents through a systematic review.

Methodology: A systematic study following the PRISMA statement for literature search was conducted, focusing on Scopus and PubMed databases. Search strategies centered on identifying MeSH terms: "hematites," "erythropoiesis," and "thrombosis."

Results: Several studies have determined a direct relationship between the use of these agents and the risk of thrombosis. Their significance was notable when associated comorbidities were considered. Furthermore, the risks were more evident when erythropoietin was used to achieve a hemoglobin target of 13-15 g/dL compared to patients with levels between 10.5 and 11.0 g/dL.